Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

March 29, 2020

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

March 10, 2018

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

April 06, 2016

News Conference News ACC 2014

ARISTOTLE: Blood Pressure Adversely Affects Stroke Risk in A-fib Patients

April 02, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

March 24, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.